Regulatory approvals for COVAXIN is in process in more than 60 countries: Bharat Biotech
Hyderabad, May 25 (UNI) Regulatory approvals for indigenously developed Covid-19 vaccine ‘Covaxin’ are in process in more than 60 countries including USA, Brazil and Hungary, according to Hyderabad-based global vaccine maker Bharat Biotech here on Tuesday.
Emergency use authorisations (EUA) have been obtained from 13 countries with more to follow.
Bharat Biotech has submitted an application to the World Health Organisation (WHO ) for EUL (Emergency Use Listing) for indigenously developed Covid-19 vaccine ‘Covaxin ‘ and regulatory approvals are expected by Jul-Sept 2021.
Most countries recommend vaccinations against COVID-19.
Unvaccinated travelers can travel with negative RT-PCR tests prior to travel, in the absence of any other country specific travel restrictions.
Bharat Biotech awaits emergency use approval from WHO for COVID-19 vaccine
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Regulatory approvals for COVAXIN is in process in more than 60 countries: Bharat Biotech
uniindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uniindia.com Daily Mail and Mail on Sunday newspapers.
Paediatric trials of Covaxin may begin in June ANI | Updated: May 24, 2021 03:06 IST
Hyderabad (Telangana) [India], May 24 (ANI): Bharat Biotech may begin paediatric trials of its Covid-19 vaccine Covaxin from June, said the company s Business Development and International Advocacy Head Dr Raches Ella on Sunday.
Holding a virtual conversation with members of FICCI Ladies Organisation (FLO) Hyderabad on All About Vaccines, he said that the company expected approval from the World Health Organisation (WHO) for Covaxin by the end of the third or fourth quarter. I am happy that our hard work is paying off well as the vaccine is working well and saving lives. We have this good feeling when we go back home from work each day. We will be soon ramping up our manufacturing capacity to 700 million doses by the end of this year, informed Dr. Raches Ella as a response to a question from a participant.